Headquarters: Lexington, MA
Founded: 2003
pulmatrix.com
Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease.
Key stats and ratios
| Q2 (Jun '17) | 2016 | |
| Net profit margin | - | -3334.49% |
| Operating margin | - | -3580.24% |
| EBITD margin | - | -2045.75% |
| Return on average assets | -96.94% | -90.49% |
| Return on average equity | -141.68% | -134.61% |
| Employees | 6 |
No comments:
Post a Comment